DFDA

Retroperitoneal Lymph Node Dissection (RPLND)

Treatment for Testicular Cancer

Typical Dosage: Surgical procedure

Effectiveness
90%
Safety Score
60%
Clinical Trials
7
Participants
50K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Surgical procedure
Time to Effect
Immediate (tumor removal)
Treatment Duration
Single procedure
Evidence Quality
HIGH
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$3,000
Side Effect Mgmt:$1,000
Total Annual:$44,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$15,000/QALY
QALYs Gained
20
Outcome-Based Costs
Cost per Remission
$49,111
Comparison vs Active Surveillance
Cost Difference
+$30,000/year
More expensive
QALY Difference
-0.05 QALYs
Worse outcomes
Dominance
No dominance
Retroperitoneal Lymph Node Dissection (RPLND) Outcomes

for Testicular Cancer

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+100%
Remission Rate
+80%
Common Side Effects
Post-operative pain
+90%
Ileus (bowel paralysis)
+30%
Retrograde ejaculation
+25%
Lymphocele
+10%
Wound infection
+7%
Small bowel obstruction
+5%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
5 active trials recruiting for Retroperitoneal Lymph Node Dissection (RPLND) in Testicular Cancer

Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma

NCT02537548ACTIVE NOT RECRUITINGNA
View Study
55 participants
INTERVENTIONAL
Loma Linda, United States +13 more
Started: Aug 28, 2015

R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma

NCT05345158RECRUITINGNA
View Study
25 participants
INTERVENTIONAL
Toronto, Canada
Started: Feb 23, 2022

A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases

NCT06932458RECRUITINGPHASE2
View Study
30 participants
INTERVENTIONAL
London, Canada
Started: Jul 17, 2025

THERApy De-escalation for TESTicular Cancer

NCT06309745RECRUITING
View Study
30 participants
OBSERVATIONAL
London, United Kingdom
Started: Jun 24, 2024

Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.

NCT06593665RECRUITINGPHASE3
View Study
142 participants
INTERVENTIONAL
Indianapolis, United States +1 more
Started: Sep 10, 2024
Completed Clinical Trials
1 completed trial for Retroperitoneal Lymph Node Dissection (RPLND) in Testicular Cancer

Role of Axumin PET Scan in Germ Cell Tumor

NCT03426865COMPLETED
View Study
10 participants
OBSERVATIONAL
Dallas, United States
Started: Mar 1, 2018